ArticleTransplant international : official journal of the European Society for Organ Transplantation2026
Long-term HLA-incompatible kidney transplant outcomes.
Article in Transplant international : official journal of the European Society for Organ Transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reshaping the landscape of HLA desensitization through immune engineering.Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many centers avoid human leukocyte antigen (HLA) -incompatible kidney transplantations due to increased risk of graft loss, although it may be the only option for highly sensitized patients. We assessed the association of pre-transplant donor-specific HLA-antibodies (DSAs) with biopsy-proven acute rejection (BPAR), antibody mediated rejection (AMR), and death-censored graft survival (DCGS). All deceased donor kidney transplantations in Finland between 2006 and 2021 were included (n = 3209), with 226 DSA-positive recipients. DSA characteristics, including specificity and mean fluorescence intensity (MFI), were collected. DSAs were associated with worse DCGS, higher risk of BPAR (HR 3.22, 95% CI 2.57-4.04), and especially AMR (HR 35.1, CI 22.4-55.1). Higher cumulative MFI was associated with lower 10-year DCGS (no-DSA 83%, ≥10,000 66%). A similar trend was seen in multivariable models (HR 1.81, CI 0.995-3.27 for MFI ≥10,000). Class II DSAs indicated higher risk for BPAR (HR 4.2 vs. HR 3.1), and AMR (HR 32.3 vs. HR 21.9), than class I DSAs. Collectively, pretransplant DSAs and higher cumulative MFI were associated with poorer graft survival, and especially class II DSAs were associated with higher risk of AMR. However, DCGS with even very high-level pretransplant DSA could be considered acceptable, supporting consideration of HLA-incompatible transplantations for highly sensitized patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.